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Abstract 
 
The Effects of Genistein, Thymoquinone, Epigallocatechin-3-gallate, 5-Fluorouracil, and 
Low Level Laser Therapy on FaDu Hypopharyngeal and Laryngeal Carcinoma Cells 
Osasu Noel Adah 
Laryngeal and hypopharyngeal carcinoma are two types of head and neck 
squamous cell carcinomas. The location of the tumor makes it hard to detect without 
complex tests.  Overall, these types of cancer are not common, and there are no simple 
screening tests for such cancers.  Due to this issue, laryngeal and hypopharyngeal 
carcinoma are usually diagnosed when signs and symptoms occur, such as sore throat, 
trouble swallowing, and constant coughing. With the use of FaDu, a head and neck 
cancer cell line of the hypopharyngeal origin, experimentation can be performed in order 
to initiate possible treatments. The standard treatments for laryngeal and hypopharyngeal 
carcinoma include conventional chemotherapy, such as 5-fluorouracil and cisplatin, 
chemo- radiation, and surgery.  The treatments used in this experiment include 5-
Fluorouracil (5-FU), Genistein (G), Thymoquinone (TQ), Epigallocatechin-3-gallate 
(EGCG), and low level laser therapy (LLLT). 5-FU is one of the most commonly used 
drugs to treat several cancers, including head and neck cancers.  G is an isoflavone 
metabolite of soy generated by gut floral bacteria and has been characterized as a possible 
prevention for cancer. TQ is an ingredient isolated from Nigella sativa and has been 
investigated for its anti-oxidant, anti-inflammatory, and anticancer activities in both in 
vitro and in vivo models. EGCG, one of the main flavonoids found in green tea, is 
considered as one of the most active molecules known for its anti-oxidant properties. 
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LLLT may enhance or decrease cell proliferation.  LLLT has shown to induce apoptosis 
in cancer such as a human colon carcinoma cell line by increasing reactive oxygen 
species (Saenko et al 2016).   
The goals of this experiment were to investigate the effects of LLLT on FaDu 
cells and to determine the effects of natural products such as G, TQ, and EGCG, as 
chemotherapeutic agents, and 5-FU (a conventional chemotherapeutic agent), combined 
with LLLT, on FaDu cells.  Specifically, cells were treated with LLLT, TQ, G, EGCG, or 
5-FU; or LLLT plus TQ, G, EGCG, or 5-FU. The cells were then harvested and cellular 
protein, intracellular glutathione levels, nitric oxide levels, and lactate dehydrogenase 
levels were evaluated.  Due to the low level of anti-cancer efficacy, G was discontinued. 
The results show a significant decrease in protein levels and cell numbers following 
treatment with TQ, however, this trend was inconsistent throughout the study.  There was 
a significant increase in nitric oxide and LDH levels following treatment with EGCG and 
EGCG + laser, and this trend remained consistent throughout the study.  However, since 
EGCG displayed similar results as EGCG + laser, LLLT possibly does not have any 
additional effect when combined to EGCG.  Overall, LLLT did not show significant 
effect on FaDu cells.  EGCG alone was shown to be the most effective treatment, in 
terms of inducing the most cellular damage and toxicity in the cancer cells.  
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Laryngeal carcinoma (cancer of the larynx) is the 2
nd
 most common cancer in the 
region involving the head and neck and is actually one of the more usual malignancies 
worldwide in men (Binshen et al 2011). Hypopharyngeal carcinoma is also a head and 
neck carcinoma that represents about 7% of all cancers of the upper aerodigestive tract. 
The prevalence of laryngeal carcinoma is 4-5 times that of hypopharyngeal carcinoma 
(Quon, 2015).  According to the National Institute of Cancer in 2016, there were an 
estimated 13,430 new cases and 3,620 deaths for laryngeal carcinoma.  In contrast, an 
estimated 3,400 adults in the United States will be diagnosed with hypopharyngeal cancer 
according to the American Cancer Society (2016). The non-specific nature of nasal and 
aural symptoms increases the likelihood to misdiagnose and leads to laryngeal and 
hypopharyngeal carcinoma diagnoses at advanced stages (stages III-IV). Some of the 
symptoms of both of these cancers include hoarseness in voice, persistent coughing, 
difficulty swallowing, and ear pain. Treatment modalities often fail and are accompanied 
by short and long term side effects of the chemotherapeutic drug, 5-Fluorouracil (5-FU).  
Some of the side effects include neutropenia, anemia, tumor lysis syndrome, infertility, 
and less commonly, angina and heart failure (Cancer Research UK, 2016).  The use of 
natural compounds, such as Genistein (G), Thymoquinone (TQ), and Epigallocatechin-3-
gallate (EGCG), which  stop cancer in different phases of the cell cycle, may provide an 
alternative to 5-FU drug regime due to possible less hazardous side effects and greater 
efficacy. 
In order to study laryngeal and hypopharyngeal carcinoma, we used a head and 
neck cancer cell line known as FaDu.  This cell line is specifically a hypopharyngeal 
carcinoma, however, it is sufficient to use in the investigation of laryngeal carcinoma due 
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to the closeness in structures, similar possible causes, signs, symptoms, and treatments.  
According to the ATCC, the FaDu line was established from a biopsy of a 
hypopharyngeal tumor removed from a patient in 1968.  With the use of FaDu, 
experimentation can be performed in order to initiate possible treatments. 
Anti-metabolites have been used to treat different types of cancers.  Fluorouracil 
(5-FU) belongs to this class of chemotherapy drugs that is specifically a pyrimidine 
antimetabolite that usually acts on cells in the G1 to S phases of the cell cycle (Tohru et 
al 2013). 5-FU works by being incorporated into DNA and RNA replicating cycles and 
preventing further cell growth.  The G1 (Gap 1) phase of the cell cycle is where the size 
of the cells increase and are being prepared for DNA replication.  The S phase of the cell 
cycle is where DNA replication/synthesis occurs.  According to results associated with 
combination chemotherapy with the DNA damaging cisplatin (CDDP) and 5-FU for 
laryngeal carcinoma, it is verified that CDDP and 5-Fu, along with radiotherapy, 
contributed to laryngeal preservation. The irreversible side effects of using CDDP and 5-
FU include peripheral neuropathy and nephrotoxicity.  The reversible side effects of 
using CDDP and 5-FU with chemotherapy include leukopenia, neutropenia, mucositis, 
and dermatitis (Furusaka et al 2013). 
The use of isoflavones as a plausible treatment for laryngeal carcinoma has been 
investigated due to their cytostatic and cytotoxic effects on the body.  Genistein (G) is 
one of the main soy isoflavones.  G has been described to be a protein kinase inhibitor, 
which can block proliferation of squamous cell carcinoma and also arrest cell growth, 
especially at the S/G2-M phase of the cell cycle (Alhasan et at 1999). The G2 (Gap 2) 
phase of the cell cycle is where the cell is still growing and is getting prepared to divide.  
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Cell cycle arrest at the G2/M phase of the cell cycle was also shown when human 
intestinal colon cancer cells (Han et al, 2013) and human oral squamous carcinoma cells 
(Ye et al 2004) were treated with G. This isoflavone initiates programmed cell death 
(apoptosis) in the malignant cells (Alhasan et al 1999).  Because of the absence of toxic 
effects and the natural biological influences of flavonoids in general, a diet rich in 
isoflavonoids, including genistein, can play a major part in the prevention of cancer 
(Alhasan et al, 1999). 
TQ is a component isolated from Nigella sativa and has been considered for its 
anti-cancer activities in both in vitro and in vivo models since its first extraction in 1960s. 
Its anti-oxidant and anti-inflammatory effects have been reported in various disease 
models, including encephalomyelitis, diabetes, asthma, and carcinogenesis (Woo et al, 
2011). TQ has also been found to induce cell death in human oral squamous carcinoma 
cells by caspase-activation dependent apoptosis (Chu et al, 2014).  Caspase is a type of 
protease. The activation of this enzyme ensures that the cellular components are degraded 
in a controlled manner, which allows for apoptosis to take place with minimal effect to 
surrounding tissues (Rathore et al, 2015).   TQ induces apoptosis in p53-dependent or 
p53-independent pathways in 6 human colorectal carcinoma cells. TQ arrests cell cycle 
progression in different types of tumor cells, specifically inducing G0/G1 arrest possibly 
through the increase in the expression of p16 and decrease in cyclin D1 in mouse 
papilloma carcinoma cells and other kinds of cancer, including acute lymphoblastic 
leukemia and prostate cancer cells (Hala et al 2004). Studies have also shown that TQ 
induces G2/M arrest in other cancer cells, including MNNG/HOS human osteosarcoma 
cells and MCF-7/DOX doxorubicin-resistant breast cancer cells (Woo et al 2011). 
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The anti-cancer effects of TQ are mediated through different modes of action:  
anti-proliferation, apoptosis induction, cell cycle arrest, ROS (Reactive Oxygen Species) 
generation, and anti-metastasis/anti-angiogenesis. TQ modulates multiple molecular 
targets, including   p53, p73, PTEN, and STAT3. There are two mechanisms that might 
contribute to growth inhibitory activities of TQ in vitro: apoptotic cell death and 
interference with the cell cycle due to increased cyclin-dependent kinases and negative 
regulator involved in G1 cell cycle control (Shoeib et al 2003). In vivo studies have 
demonstrated that TQ decreases CDDP-induced side effects, including nephrotoxicity, 
without compromising its antitumor activity (Shoeib et al 2003). 
EGCG is a flavonoid found in green tea and is known for its antioxidant 
properties (Legeay et al 2015). EGCG causes cell cycle arrest in the G1 phase in oral 
squamous cell carcinoma cells by upregulating B-cell translocation gene 2, which is a 
regulatory protein of the cell cycle (Lee et al 2015).   Studies have also shown that EGCG 
inhibits the self-renewal capacity of head and neck squamous carcinoma cancer stem 
cells by suppressing their sphere-forming capacity, which is a measure of tumorigenicity 
(Lee et al 2013).  EGCG inhibits enzyme activities, such as NFĸB, in head and neck 
carcinoma cells, which result in suppression of cell proliferation, enhancement of 
apoptosis, and inhibition of cell invasion, angiogenesis, and metastasis (Chung et al 
2012).  NFĸB is known for its role in inflammation, and EGCG blocks this enzyme from 
being activated (Zhe et al, 2004).  Overall, EGCG seems to be one of the most promising 
naturally-derived compounds that demonstrate tumor suppressive effects on animal 
carcinogenesis models, mouse xenograft models, and several cancer cell lines (Muneyuki 
et al 2011). 
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Low level laser therapy (LLLT) involves exposing cells or tissue to low levels of 
red and near infrared (NIR) light, and is referred to as “low level” because of  its use of 
light at energy densities that are low as compared to other forms of laser therapy that are 
used for ablation, cutting, and thermally coagulating tissue (Hamblin, 2008). From 
observation, it appears that LLLT has a wide range of effects at the molecular, cellular, 
and tissue levels.  There are three major roles that LLLT is typically used for:  wound 
healing, tissue repair, and inflammation relief (Hamblin, 2008).  LLLT has been used 
clinically by physical therapists to treat a variety of musculoskeletal aches and pains, by 
dentists to treat inflamed oral tissues and to heal ulcerations, by dermatologists to treat 
edema, ulcers, burns, and dermatitis, by orthopedists to relieve pain and treat chronic 
inflammation and autoimmune diseases, and more (Hamblin, 2008). Within the cell, there 
is strong evidence to suggest that LLLT acts on the mitochondria to increase adenosine 
triphosphate (ATP) production, modulating reactive oxygen species (ROS). LLLT has 
shown promise for down regulating inflammation by reducing the presence of reactive 
oxygen species (ROS).   However, there are limited studies on how LLLT affects cancer 
cells. Studies involving laser treatment on bone tumors have shown that a wavelength of 
830nm increased osteoblast proliferation significantly and reduced osteosarcoma cells at 
an energy level of 10 J/cm
2
 (Renno et al 2007). LLLT has limited systemic effects and 
may be implicated in toxic reduction in the body (Rhee et al 2012).   
 
Goals, Hypotheses, and Specific Aims 
In the literature, studies that tested the dual effects of LLLT and anti-cancer 
agents such as 5-FU, G, TQ, and EGCG are limited.  Therefore, the goals of this study 
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were to 1) determine the effects of LLLT on FaDu cancer cells and to 2) determine the 
effects of natural products or a conventional chemotherapeutic agent, 5-FU, in 
combination with LLLT on cancer cell growth. 
Hypothesis I:  FaDu cancer cells exposed to laser treatments will show a reduction 
in cell number and viability. 
Specific Aim:  To determine the effect of 830 nm of laser light on FaDu cells, protein 
levels were measured as a correlate to cell number, and cell function was monitored via 
glutathione levels at 24, 48, and 72 hours post LLLT.  LLLT effects were compared to 5-
FU, G, EGCG, and TQ at their pre-determined, respective time-dependent IC50’s. 
Hypothesis II:  FaDu cancer cells exposed to laser treatment in combination with 
single-dose cell cycle specific drugs/compounds will show a greater reduction in cell 
numbers than compared to the administration of separate treatments. 
Specific Aim: To determine the effect of 830 nm of laser light on FaDu cells, cell 
function, and after 24, 48, and 72 hours in combination with chemotherapeutic drugs (5-
FU) and other natural products at their time-dependent IC50’s. 
Hypothesis III:  Treatment cell cycle specific drugs/compounds and additional 
treatment of LLLT will show a greater eradication or suppression cancer cell 
growth compared to single-dose treatment of LLLT. 
Specific Aim:  To determine the effects of additional  treatment with 830 nm laser light in 
combination with chemotherapeutic drug (5-FU) and other compounds (TQ and EGCG) 
on FaDu cell numbers and cell function after 24, 48, and 72 hours. 
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Background of LLLT and treatment in study: 
In phase 1, the cells were treated with each of the treatments (TQ, EGCG, and 5-
FU).  The cells were then placed in the incubator for 30 minutes.  Next, the laser 
treatment was added to the designated cells.  The cells were then harvested at 24, 48, and 
72 hours.  In phase 2, the cells were treated with each of the treatments (TQ, EGCG, and 
5-FU).  The cells were then placed in the incubator for 30 minutes.  Next, laser treatment 
was added to the designated cells that were to be harvest at 24, 48, and 72 hours.   The 
same day that the 24-hour cells were being harvested, laser treatment was done again for 
the 48 and 72-hour cells.  The same day that the 48-hour cells were being harvested, laser 
treatment was done the third time for the 72-hour cells.  The next day, the 72-hour cells 
were harvested. 
The laser (830 nm) used in this study has three diodes on the face.  The mean 
power of each diode is 30mW and the pulse duration lasts for 33 seconds.  Therefore, a 
total of about 3 Joules of energy is emitted from the diodes and the duration lasts for 33 
seconds.  A total of 10 Joules is needed for this present study; therefore, the laser duration 
cycle was repeated once.  Next, one of the diodes was covered to give a total 2 Joules, 
and then repeated once.  Therefore, the total duration that the laser was treating the cells 
was about 132 seconds. Figure 1 shows a diagram of the laser used in the study. 
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Diode Switch 
 
 
  
Figure 1:  Diagram of Low Level Laser (Microlight ML830) 
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Overview of Laryngeal Carcinoma 
Laryngeal carcinoma (head and neck squamous cell carcinoma) is a malignancy 
that represents about 2-5% of cancers, but represents about 85-90% of squamous cell 
carcinomas (Wolf 2016).  Symptoms of laryngeal and hypopharyngeal carcinoma include 
voice changes (hoarseness), constant sore throat, coughing, trouble or pain while 
swallowing, earache, trouble breathing, weight loss, and mass in neck (American Cancer 
Society, 2015).  The exact etiological factors for laryngeal and hypopharyngeal 
carcinoma are unknown, but many co-factors, including tobacco smoking, alcohol 
consumption, poor diet, and depressed immune system, have presumed contributions 
(Mastronikolis et al 2012). 
The 5-year survival rate for laryngeal carcinoma depends on the location of the 
cancer—glottis, supraglottis, or subglottis. Cancer in the glottis region, part of the larynx 
that include the vocal cords, has a 5-year survival rate of 90% for stage I, 74% for stage 
II, 56% for stage III, and 44% for stage IV.  Cancer in the supraglottic region, part of the 
larynx that is above the vocal cords, has a 5-year survival rate of 59% for stage I, 59% for 
stage II, 53% for stage III, and 34% for stage IV. Cancer is the subglottic region, part of 
the larynx below the vocal cords, has 5-year survival rate of 65% for stage I, 56% for 
stage II, 47% for stage III, and 32% for stage IV.  The 5-year survival rate for 
hypopharyngeal carcinoma (area around vocal cords) is 53% for stage I, 39% for stage II, 
36% for stage III, and 24% for stage IV (American Cancer Society, 2016).  Laryngeal 
and hypopharyngeal carcinoma are staged according to the Tumor-Node-Metastasis 
(TNM) classification system (stages 0-IV). This system takes into account the size and 
location of the tumor (T), lymph node involvement (N), and presence of distant 
metastasis (M) (Mastronikolis et al 2012). There are five stages of laryngeal carcinoma. 
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In Stage 0, the cancer cells are only growing in the inner lining layer of the larynx; there 
is no evidence the cancer has spread to the lymph nodes or beyond.  In Stage I, the tumor 
is only in the vocal cords; there is no evidence the cancer has spread to the lymph nodes 
or beyond.  In Stage II, the tumor is growing into the supraglottis/subglottis and/or the 
vocal cords do not move normally, but there is no evidence of lymph node involvement 
or distant metastasis.  In Stage III, the tumor is in the larynx with vocal cord paralysis. 
The tumor could also be growing into the paraglottic space or into the inner part of the 
thyroid cartilage.  Notably in stage III, the cancer is likely to have spread to a single 
lymph node on the same side of the neck as the tumor, and the node is < 3 cm across. It is 
possible that there is no evidence the cancer has spread to the lymph nodes, and it has not 
spread to distant sites.  In Stage IV, either the tumor has grown through the thyroid 
cartilage and/or is growing into tissues beyond the larynx, or the tumor is growing into 
the tissue anterior to the spine in the neck (the prevertebral space), surrounds a carotid 
artery, or is growing down into the space between the lungs.  The cancer could possibly 
spread to at least 1 lymph node that is larger than 6 cm across and possibly spread to 
distant sites (American Cancer Society, 2015).   Survival decreases by more than one 
third when clinically positive lymph nodes are present. There is a five-year disease free 
survival of patients with supraglottic cancer is 80% for stages I-II, 70% for stage III and 
40% for stage IV. Patients with glottic cancers have a better long-term prognosis. There 
is a five-year disease free for stages I-II is 85%-90%, for stage III is 75% and for stage IV 
is 45%-50%. However, in cases with an extremely advanced local and regional disease 
the overall 5-year survival is less than 5% (Mastronikolis et al 2012). There are also five 
stages for hypopharyngeal carcinoma. In stage 0, there is no evidence of primary tumor, 
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or any regional lymph node or distant metastasis.  In stage I, the tumor is limited to one 
subsite of the hypopharynx, and there is no regional lymph node or distant metastasis.  In 
stage III, the tumor is either greater than 4 cm in dimension from extension to the 
esophagus.  The tumor could possibly be limited to 1 subsite of the hypopharynx and/or 
≤2cm in greatest dimension or invade more than 1 subsite.  Metastasis could be in a 
single lymph node ≤3 cm in greatest dimension and/or no distant metastasis. In stage IV, 
the tumor could invade the thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central 
compartment soft tissue and could range from having no regional lymph node metastasis 
to  metastasis in a lymph node >6cm in greatest dimension. Distant metastasis is also a 
possibility (Stevenson, 2016). The larynx and pharynx are illustrated in figure 2. 
 
 
Figure 2:  Illustration of the larynx and pharynx showing labeled parts 
 
Cellular changes in Laryngeal and Hypopharyngeal Carcinoma: 
Common cellular changes that occur in laryngeal and hypopharyngeal 
carcinogenesis include those involving, the tumor suppressor p53, the proto-oncogene 
cyclin D1, and tumor suppressor p16 (Williams et al, 2015; Fu et al, 2007).  p53 is a 
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nuclear phosphoprotein and tumor protein involved in gene transcription, apoptosis, DNA 
repair and synthesis, and cell cycle regulation (Mastronikolis, 2012).  p53 is the 
gatekeeper of DNA integrity at the R checkpoint of the cell cycle. This protein is mutated 
in more than 50% of human tumors. p53 point mutations, deletions, and inactivation 
occur in the shift from the pre-invasive to the invasive state of laryngeal carcinoma 
(Mastronikolis, 2012).  Mutations include loss of G1/S checkpoint control and the 
inability for apoptosis to regularly occur. The inactivation of p16 and p53 occur early in 
the development and progression of laryngeal carcinoma (Williams et al, 2015).  Cyclin 
D1 is involved in cell cycle progression and interacts with cyclin-dependent kinases. 
When cyclin D1 gene amplification is observed in precancerous and cancerous lesions, it 
is always overexpressed.  In this state of increased expression, cyclin D1 drives more 
cells into the G2/M phase of the cell cycle (Mastronikolis et al., 2012). 
 
Standard of treatment of laryngeal and hypopharyngeal carcinoma by stage: 
In stage 0 for laryngeal carcinoma, the cancer is usually in the glottic area.  Vocal 
cord stripping, laser surgery, or radiation therapy are mainly used as treatment options  In 
stage I and II of laryngeal carcinoma, either radiation without surgery or partial 
laryngectomy usually takes place.  Particularly, glottis cancers are usually treated by 
removing the vocal cords.  Supraglottic cancers, the lymph nodes are usually removed.  
In stage III and IV of laryngeal carcinoma, treatment is usually some combination of 
surgery, radiation, and/or chemotherapy.  Initial treatment usually includes surgery or 
chemotherapy (common chemotherapeutic drugs include cisplatin and 5-FU) with 
radiation.  In stage I for hypopharyngeal carcinoma, surgery and/or radiation are usually 
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the main options for initial treatment.  Surgery usually includes removing all or part of 
the pharynx along with the lymph nodes on the sides of the neck.  In stages II, III, IV for 
hypopharyngeal carcinoma, the first option is usually to remove the pharynx, larynx, and 
lymph nodes in neck area, accompanied by radiation or radiation with chemotherapy.  
Treatment first with chemotherapeutic drug, such as cisplatin, along with radiation, is 
another option (American Cancer Society, 2016).  
Tables 1-5 below display different studies involving the treatments and their findings. 
 
Table 1: Studies on the Effect of Genistein 
 
Year Author(s) Cell Line/Type Major Findings 
1999 Alhasan et al HN4 squamous 
cell carcinoma 
cell line 
--genistein inhibits proliferation of a 
squamous cell carcinoma cell line 
--caused cell cycle arrest at the S/G2-M 
phase and induced apoptosis 
-- shown to inhibit cell proliferation 
and to induce cell cycle arrest at the 
G2-M phase in breast, prostate, and 
jurkat T cell leukemia cell lines. 
2010 Tokkalov et al p53-deficient cells 
(H1299, FaDu) 
--genistein-based therapy may have 
antagonistic effects when combined 
with mitotic poisons. 
--proposed therapeutic strategy allows 
protection of p53 wild type cells from 
taxol and selectively increases 
apoptosis in p53-deficient cells. 
2010 Johnson et al SCC15 and 
SCC25 squamous 
cell carcinoma 
cell lines 
--genistein inhibited SCC15 and 
SCC25 cell growth. 
--induced a decrease in 
phosphorylation of ERK and Akt at 
treatment concentrations of 20, 50 and 
100 μM. 
(Akt accelerates tumor progression) 
2013 Han et al human intestinal 
colon cancer 
Caco-2 cells 
--genistein significantly suppressed cell 
proliferation. 
--demonstrated to modulate cell cycle 
distribution through accumulation of 
cells at G2/M phase, with a significant 
decreasing effect of Cyclin B1 and 
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Serine/threonine-protein kinase 2 
(Chk2) proteins expression 
2013 Zheng et al SK-N-SH human 
neuroblastoma 
cells 
-- Cells were arrested at the G2/M 
phase by genistein 
-- estradiol- or environmental 
endocrine disruptor-induced 
proliferation of human neuroblastoma 
cells is effectively abolished by 
genistein, likely in a cell cycle- and Akt 
pathway-dependent manner 
2013 Hara et al participants with 
gastric cancer 
-- no association of plasma isoflavone 
concentrations with gastric cancer risk 
2011 Ayhen et al nasopharyngeal 
carcinoma cell 
line CNE 
-- genistein induced a G2/ M cell cycle 
arrest 
--induces nasopharyngeal cancer cell 
early apoptosis rate 
-- characteristic morphological changes 
of apoptosis in CNE cells was observed 
after treated by genistein 
2004 Ye et al human oral 
squamous 
carcinoma line 
(SCC-25) 
-- genistein inhibited SCC-25 cell 
growth via G2/M phase arrest. 
-- significant decrease of proliferating 
cell nuclear antigen expression in these 
cells after treatment 
2001 Akimoto et al human esophageal 
squamous cell 
cancer cell lines, 
TE-1 (p53, 
mutant) and TE-2 
(p53, wild) 
-- Genistein (30 microM) greatly 
enhanced radiosensitivity in cell lines 
by suppressing radiation-induced 
activation of survival signals, p42/p44 
extracellular signal-regulated kinase 
and AKT/PKB 
2000 Alhasan et al HN4 squamous 
cell carcinoma of 
the head and neck 
cell line (HNSCC) 
-- down-regulation of Cdk1, and 
CyclinB1, and up-regulation of the 
cyclin dependent kinase (Cdk) inhibitor 
p21WAF1--may be responsible for the 
induction of cell cycle arrest and 
apoptosis 
2012 Li et al Neuroblastoma 
(NB) cell line 
--genistein, is an epigenetic modifier 
able to decrease hypermethylation 
levels of CHD5, and enhances the 
expression of CHD5 as well as p53 
(tumor suppressor genes), which may 
contribute to inhibition of NB growth 
in vivo and tumor micro-vessel 
formation 
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Table 2: Studies on the Effect of Thymoquinone 
 
 
Year Author(s) Cell Line/Type Major Findings 
2012 Woo et al Review:  tumor 
xenograft mice 
models for colon, 
prostate, pancreatic 
and lung cancer 
--review: anti-oxidant/anti-
inflammatory and anticancer effects 
of TQ with a focus on its molecular 
targets, 
2007 Roepke et al human 
osteosarcoma cells 
-- TQ induces p53-independent 
apoptosis in human osteosarcoma 
cells 
2010 Gurung et al Glioblastoma cells -- TQ induces DNA damage, 
telomere attrition by inhibiting 
telomerase and cell death in 
glioblastoma cells 
2003 Shoieb et al canine 
osteosarcoma 
(COS31), human 
breast 
adenocarcinoma 
(MCF7), human 
ovarian 
adenocarcinoma 
(BG-1) and Madin-
Darby canine 
(MDCK) cell lines 
--TQ induced apoptosis of COS31 
and decreased the number of COS31 
cells in S-phase and increased cells in 
G1-phase, indicating cell cycle arrest 
at G1 
2012 Lei et al gastric cancer cells 
xenograft tumor 
mouse model 
-- pretreatment with TQ significantly 
increased the apoptotic effects 
induced by 5-FU in gastric cancer cell 
lines in vitro 
-- TQ enhanced the 5-FU-induced 
killing of gastric cancer cells by 
mediating the downregulation of the 
anti-apoptotic protein bcl-2, the 
upregulation of the pro-apoptotic 
protein bax, and the activation of both 
caspase-3 and caspase-9 
2015 Wilson et al ID8-NGL mouse 
ovarian cancer cells 
-- TQ reduced proliferation and 
increased apoptosis in ID8-NGL 
tumors after 10 and 30 day treatment 
-- Prolonged TQ treatment did not 
significantly alter tumor number or 
mass compared to vehicle, but 
exerted an overall deleterious effect 
by stimulating ascites formation 
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2015 Parbin et al MCF-7 
breast cancer cells 
-- TQ elicited downstream effects of 
induction of the pro-apoptotic gene 
Bax, down regulation of the anti-
apoptotic gene Bcl-2 and arrest of the 
cell cycle at the G2/M phase. 
--the result of a higher cytotoxicity of 
TQ towards MCF-7 
breast cancer cells in comparison to 
normal cells indicates the potential of 
TQ to be an anticancer drug 
2015 Harpole et al SK-OV-3 
Ovarian Cancer 
 
-- increase in nitric oxide following 
the administration of EGCG alone 
and in combination with TQ 
compared with TQ alone or untreated 
control cells with the difference being 
about three-fold higher 
2015 Dehghani et al human breast 
adenocarcinoma 
cell line (MCF7) 
-- Proliferation of MCF7 cells was 
significantly inhibited by TQ and 
nanothymoquinone in a 
concentration-dependent manner in 
defined times 
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Table 3:  Studies on the Effect of 5-Fluorouracil 
Year Author(s) Cell Line/Type Major Findings 
2013 Ghiringhelli et al myeloid-
derived 
suppressor cells 
-- 5FU-driven activation of the NLRP3 
inflammasome in MDSCs promotes 
tumor angiogenesis by eliciting TH17 
responses that compromise anticancer 
immunity 
2013 Zhang et al Colorectal 
cancer 
-- detection for G2194A, T85C and 
T464A could predict ~13% of 5-FU 
severe toxic side effects 
2013 De la Cueva et al Colorectal 
cancer-tumor 
derived cell 
lines/mouse 
xenograft 
models 
-- both ChoKa and 5-Fu  in 
combination display a synergistic anti-
tumor effect  due to ChoKa inhibitors-
driven  modulation  of  the  
metabolization  of  5-FU. 
 
2012 Chen et al Hep-2/5-Fu Cell 
line 
-- the drug resistance cell line had 
slower growth rate and larger size 
-- Hep-2/5-Fu cell line showed cross 
drug resistance to 5-Fu, cisplatin and 
vincristine 
 
2013 Furusaka et al Squamous cell 
carcinoma of 
the glottis 
larynx 
-- synergistic effects of anticancer 
chemotherapy combined with 
chemoradiation therapy for squamous 
cell carcinoma caused marked cancer 
tissue degeneration 
-- Side effects included leukopenia, 
neutropenia, mucositis, and dermatitis 
2011 Ma et al FaDu cell line 
and resistant 
cell line, 
FaDu/T 
-- multidrug resistant sensitivities of the 
FaDu/T cells to cisplatin (DDP), 5-FU, 
doxorubicin (Dox) and vincristine 
(VCR) were investigated 
-- percentages of FaDu/T cells in the 
G0/G1 and G2/M phases were 
increased while the cell percentage in 
the S phase decreased as compared with 
the percentages of FaDu cells. The anti-
apoptotic ability increased prominently, 
as the index of apoptosis decreased 
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Table 4:  Studies on the Effect of LLLT 
 
Year Author(s) Model/Cell 
Type 
Major Findings 
2013 Firat et al diabetic rats -- LLLT elicits a positive healing effect 
on palatal mucoperiostal wounds, and 
modulates the oxidative status 
-- reduced numbers of inflammatory 
cells, and increased mitotic activity of 
fibroblasts, collagen synthesis, and 
vascularization 
2013 Sperandio et al cells (DOK) and 
oral cancer cells 
(SCC9 and 
SCC25) 
-- LLLT (660 nm or 780 nm;2.05, 3.07 
or 6.15 J/cm²) can modify oral 
dysplastic cells (DOK) and oral cancer 
cells (SCC9 and SCC25) growth by 
modulating the Akt/mTOR/CyclinD1 
signaling pathway; 
--LLLT significantly modified the 
expression of proteins related to 
progression and invasion in all the cell 
lines, and could aggravate oral cancer 
cellular behavior 
2009 Frigo et al melanoma cells 
(B16F10) in 
mice 
-- Irradiation should be avoided over 
melanomas as the combination of high 
irradiance (2.5 W/cm(2)) and high dose 
(1050 J/cm(2)) significantly increases 
melanoma tumor growth in vivo 
2014 Gomes et al tongue 
squamous 
carcinoma cell 
line (SCC25) 
-- LLLT exerts a stimulatory effect on 
proliferation and invasion of SCC25 
cells 
2003 Kreisler et al human 
periodontal 
ligament 
fibroblasts 
(PDLF) 
-- 809-nm diode laser; 1.96-7.84 Jcm-2 
-- irradiated cells revealed a 
considerably higher proliferation 
activity than the controls. The 
differences were significant up to 72 h 
after irradiation 
2002 Kreisler et al human gingival 
fibroblasts 
(HGF) in vitro 
-- 809-nm semiconductor laser; 1.96-
7.84 J/cm(2) 
--  irradiated cells revealed a 
considerably higher proliferation 
activity; differences were highly 
significant 24 hour after irradiation but 
decreased in an energy-dependent 
manner after 48 and 72 hour after 
irradiation 
21 
 
2010 Peplow et al **review—
human and 
animal cells in 
culture 
-- results consistently demonstrated the 
potential of laser irradiation to affect 
cellular proliferation in a wavelength- 
and dosage-dependent manner 
 
 
2002 Pinheiro et al Laryngeal 
carcinoma cells-
-  H.Ep.2 cells 
--670nm laser irradiation led to an 
increased cell proliferation when 
compared to both control and 635nm 
irradiated cells 
--best cell proliferation was found with 
670nm laser irradiated cultures exposed 
to doses of doses of 0.04 to 0.48 J/cm2 
-- both dose and wavelength are factors 
that may affect cell proliferation of 
HEP2 cells 
2005 Werneck et al HEP2 cells -- Time, treatment, and wavelength 
significantly influenced the 
proliferation process of HEP2 cells 
--685 and 830 nm 
2007 Renno et al normal primary 
osteoblast 
(MC3T3) and 
malignant 
osteosarcoma 
(MG63) cell 
lines 
-- Osteoblast proliferation increased 
significantly after 830-nm laser 
irradiation (at 10 J/cm(2)) but decreased 
after 780-nm laser irradiation (at 1, 5, 
and 10 J/cm(2)) 
-- Alkaline phosphatase (ALP) activity 
in the osteoblast line was increased after 
830-nm laser irradiation at 10 J/cm(2) 
-- each cell line responds differently to 
specific wavelength and dose 
combinations 
2012 Rhee et al Cochlear hair 
cells 
-- LLLT may promote hair cell survival 
following gentamicin damage in the 
cochlea 
2016 Saenko et al HCT-116 and 
CHO-K cells 
(human colon 
carcinoma cell 
line) 
--Laser irradiation has induced a dose-
dependent cell death via increasing 
intracellular reactive oxygen species 
(ROS) concentration, increase of DNA 
damage, decrease of mitochondrial 
potential, and reduced glutathione. 
--the increase of the intracellular ROS 
concentration induced by mitochondrial 
damage contributes to the damaging 
effect of the laser irradiation at 1265 nm 
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2016 Bartos et al HEI-OC1 
auditory cells 
--Near infrared photobiomodulation 
therapy at 810 nm, 30 mW/cm
2
 , 100 
seconds, 1.0 J, 3 J/cm
2
 changed  
mitochondrial metabolism and 
oxidative stress response for up to 24 
hours post treatment. 
2015 Giuliani et al Mouse 
Embryonic 
Fibroblast 
(MEF) 
--LLLT at 670 nm, when dispensed in 
pulsed mode, modifies mitochondria 
network dynamics, as well as 
expression level of mRNA encoding for 
selective matrix proteins in MEF 
2014 Agrawal et al Multiple tissues --LLLT has been used for nearly 50 
years to enhance tissue healing and to 
relieve pain, inflammation and swelling. 
The photons are absorbed in 
cytochrome(c) oxidase (unit four in the 
mitochondrial respiratory chain), and 
this enzyme activation increases 
electron transport, respiration, oxygen 
consumption and ATP production. 
 
2016 Zhou et al stress-induced 
premature 
senescence 
(SIPS) model 
--5-aminolevulinic acid photodynamic 
therapy (ALA-PDT) elicits oxidative 
damage and apoptosis in photoaged 
fibroblasts in vitro, which may be the 
basis for the rejuvenating effects on 
photoaged skin. 
2014 Mocan et al pancreatic 
cancer cells 
(PANC-1) 
--multi-walled carbon nanotubes and 
polyethylene glycol (PEG) laser 
mediated treatment (808 nm, 2W) leads 
to mitochondrial membrane 
depolarization that activates the flux of 
free radicals within the cell and the 
oxidative state mediate cellular damage 
in PC cells via apoptotic pathway. 
2013 Huang et al Mouse cortical 
neuron 
--LLLT increases ROS in normal 
neurons, it reduces ROS in oxidatively-
stressed neurons. In both cases 
mitochondrial membrane potential is 
increased 
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Table 5:  Studies on the Effect of EGCG 
 
Year Author(s) Cell Line/Type Major Findings 
2015 Legeay et al **Review -- EGCG modulates cellular and 
molecular mechanisms of various 
symptoms leading to metabolic 
syndrome 
2012 Min et al **non-specific -- preferential death of cancer cells by 
EGCG could be caused by the cancer-
specific induction of ROS and 
epigenetic modulation of expression of 
apoptosis-related genes, such as hTERT 
2003 Gupta et al human prostate 
carcinoma cells 
-- EGCG causes an induction of G1 
phase ckis, which inhibits the cyclin-
cdk complexes operative in the G0/G1 
phase of the cell cycle--causes an arrest, 
leading to apoptotic cell death 
2015 Flores-Perez et al A549 lung 
cancer cells 
-- abrogation of HDGF by EGCG 
enhances cisplatin-induced apoptosis 
and sensitize A549 cells to 
chemotherapy 
-- Cell death was associated to 
increased apoptosis, disruption of the 
mitochondrial membrane potential, and 
activation of caspase-3 and caspase-9 
2015 Irimie et al SSC-4 human 
oral squamous 
cell carcinoma 
(OSCC) 
-- EGCG treatment suppresses cell 
proliferation of SSC-4 human oral 
squamous cell carcinoma (OSCC), 
(dose- and time-dependent) 
--activation of apoptosis and autophagy 
in response to EGCG exposure in SSC-
4 cells 
2015 Lee et al Oral squamous 
cell carcinoma 
(OSCC) 
-- EGCG attenuates cell proliferation of 
OSCC cells by upregulating BTG2 
expression via p38 and ERK pathways 
2015 Liu et al human 
esophageal 
squamous cell 
carcinoma cell 
lines, Eca-109 
and Te-1 
--EGCG inhibits proliferation and 
induces apoptosis through ROS 
production, caspase-3 activation, and a 
decrease in VEGF expression in vitro 
and in vivo 
-- Tumor cells were arrested in the G1 
phase 
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2013 Lee et al head and neck 
squamous 
carcinoma 
(HNSC) 
-- EGCG inhibits the self-renewal 
capacity of HNSC CSCs by 
suppressing their sphere forming 
capacity, and attenuates the expression 
of stem cell markers, such as Oct4 and 
Sox2 
-- EGCG decreased the transcriptional 
level of Notch, resulting in the 
inhibition of Notch signalling 
2009 Wang et al Laryngeal 
squamous cell 
carcinoma 
(LSCC) cell 
line Hep-2 
-- treatment of Hep-2 cells with EGCG 
decreased the cell viability, inhibited 
the growth and proliferation, induced 
apoptosis and increased the activity of 
caspase-3 in a dose-dependent manner 
--EGCG-treatment repressed 
telomerase activity effectively in a 
concentration-dependent manner 
2010 Lee et al human 
laryngeal 
epidermoid 
carcinoma of 
the larynx Hep2 
cells 
-- p53-mediated mitochondrial pathway 
and the nuclear translocation of AIF 
and EndoG play a crucial role in 
EGCG-induced apoptosis of human 
laryngeal epidermoid carcinoma Hep2 
cells 
2011 Muneyuki et al head and neck 
squamous cell 
carcinoma 
(HNSCC) 
--EGCG has shown clinical efficacy 
and unique biological effects on lipid 
rafts that are an important platform of 
numerous biophysical 
functions including RTKs signalings. 
 
2011 Joseph et al squamous cell 
carcinoma of 
the head and 
neck (SCCHN) 
-- EGCG modulates several key 
molecular signaling pathways at 
multiple levels and has synergistic or 
additive effects when combined with 
many other natural or synthetic 
compounds (review) 
2009 Chung et al **review --EGCG inhibit enzyme activities and 
signal transduction pathways, resulting 
in the suppression of cell proliferation 
and enhancement of apoptosis, as well 
as the inhibition of cell invasion, 
angiogenesis and metastasis 
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Materials and Methods 
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 Cells and Culture:  The FaDu cell is a squamous cell carcinoma originating from a 
hypopharyngeal tumor removed from a patient in India (Wiley).  For this experiment, the 
FaDu cells were obtained from the American Type Culture Collection (ATCC, Rockville, 
MD).  The FaDu cell line was grown in 90% Eagle’s Minimum Essential Medium 
(EMEM) with 10% fetal bovine serum (FBS).  FaDu cells were cultured and plated in 
either 24-well tissue culture plates at a density of 1.0 x 10
6
 cells per well or in 6-well 
tissue culture plates at 5 x 10
6
 for the laser experiments since the area of the well 
(9.5cm
2
) was comparable to the head of the laser. The cells were then incubated in a CO2 
(5% CO2 and 95% air) at 37˚C until treatment.  
Treatment of Cells: For the first set of experiment in the 24 well plates, cells in the first 
row were left untreated and served as the control and cells in rows 2-4 were treated with 
IC50 doses of either Genistein (25 mM), TQ (16 µM ) and 5-FU (16 µM).   For 
experiments in 6 well plates involving LLLT, cells were treated with laser or IC50 doses 
of EGCG, TQ, and 5-FU, and placed in the incubator for 30 minutes prior to LLLT 
treatment and then incubated for 24, 48, and 72-hour intervals.  For LLLT, cells were 
treated with 10 Joules (1.05 J/cm
2
) at 830 nm wavelength.  (Genistein was replaced with 
the IC50 dose of EGCG (3 µM)).   Additional experiments were performed with daily 
treatments of LLLT and followed for 24, 72, and 96 hours (change in harvest time was 
used since the doubling time for these cells was found to be 48 hours) of treatment with 
the chemotherapeutic agent 5-FU for 30 minutes followed by daily treatments with 
LLLT.  In the final experiments, the cells were treated and incubated for 30 minutes with 
the IC50 doses with TQ, 5-FU, EGCG, followed daily laser therapy.  In the first phase of 
this set, the cells were treated for one day, then LLLT was performed for each day (24, 
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48, and 72 hours).  In the second phase, the cells were treated each day, 30 minutes prior 
to LLLT being performed. Table 6 below summarizes the experimental design and 
treatments for each set and phase. 
 
Table 6: Experimental Design 
Exp. Process G TQ 5-FU EGCG LLLT Assay 
1 24, 48, 72 hours; 
continuous 
treatment 
25 mM 16 µM 16 µM X X Protein 
Glut 
2 24, 72, 96 hours; 
continuous 
treatment 
X X 16 µM X 830 nm 
10 J 
Protein 
Glut 
3 24, 48, 72 hours. 
Phase 1:  
continuous 
treatment; LLLT 
on day 0 
Phase 2: 
Continuous 
treatment with 
additional LLLT 
treatment each 
day 
X 16 µM 16 µM 3 µM 830 nm 
10 J 
Protein 
Glut 
NO 
LDH 
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Cell Collection: After the allotted times (24, 48, 72, or 96-hour period after treatments), 
the supernatants from each group were collected and placed into appropriate labeled 
microcentrifuge tubes and were frozen.  After the supernatant was collected, 1mL of PBS 
was added to the wells (6- and 24-well plates).  All of the wells that contained PBS were 
scraped, and the cells were collected in microcentrifuge tubes.  The microcentrifuge tubes 
containing the cells with PBS were placed into the centrifuge at 1500-2000 rpm for ten 
minutes.  The PBS was then removed from the microcentrifuge tubes down to the 0.1 
mark.  The pellet was left, and another 1mL of PBS was added to the tubes and 
centrifuged again. The PBS was removed again down to the 0.1 mark, the 300µL of PBS 
was added to the tubes containing the pellet.  The tubes were vortexed to resuspend the 
cells.  The cells were frozen for at least one day prior to being assayed, 
Biochemical Analysis:  Colorimetric microtiter plate endpoint assays were performed to 
determine concentrations of protein, reduced glutathione, and nitric oxide. Lactate 
dehydrogenase activity was determined using spectrophotometric analysis of reduction of 
NADP.  Cellular protein was determined to evaluate cell viability; intracellular 
glutathione was used to determine cellular stress and viability.  Lactate dehydrogenase 
activity and nitric oxide levels were determined in the supernatants for cell toxicity and 
damage.  The microtiter plates were analyzed using a Spectra plate reader to determine 
concentration using the Magellan curve fit software. 
Protein Assay:  The initial step in the BCA protein assay process involved making the 
standard solution.  Eight microcentrifuge tubes were used for the standard.  Albumin 
Standard Ampule (500 µl, 2mg/mL) was placed in the first tube, and then 500µL of PBS 
were placed in all eight tubes.  A serial dilution was done, where 500µL were taken out 
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of each consecutive tube and placed into the next one, but not in tube eight.  These 
standard solutions (25µL) were added into the first two columns of the 96-well plate 
followed by 25µL of cells into the remaining wells.  The working reagent was determined 
by multiplying the number of wells with standards and cells by 0.2mL, which is equal to 
the total working reagent (WR).  The equation, 1/50=X/total amount of WR gave the 
amount of reagent B when solved for X. By subtracting the amount of regent B from the 
total WR, the amount of reagent A was calculated.  After 200 µL of the WR was added to 
all the standards and cells, the cell plate was incubated (37˚C) for 30 minutes, covered.  
After the incubation period, the plate was read using the Magellan software. The 
parameters:  1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0.015625, and 0 were used to compare 
the standards. Wavelength (540 nm) was used for protein assay analysis. 
Glutathione Assay:  The initial steps in the glutathione assay were to prepare fresh 
reagents.  The chemicals used in the preparation included NADPH, DNTB, GSH 1, and 
2, phosphate buffer, EDTA, and reductase.  The standards are made by taking eight glass 
test tubes and placing 100µL of GSH 2 into tubes 1 and 2, then adding 100µL of distilled 
water into tubes 2-8, then doing a serial dilution, where 100µL was taken out of each 
consecutive tube starting from tube two and ending at tube seven.  Each standard (50 µL) 
was added into the 96-well plate, then 50µL of the cells were also added into the plate.  
Depending on how many samples being tested, the mixed reagent that was prepared 
initially was added to the standard and cell samples (100µL).  The ratio of the amount of 
chemicals to use to make the mixed reagent: 1 to 1 to 1.15 (DNTB, NADPH, EDTA + 
Buffer).  After the mixed reagent was added, the plate was read using the Magellan 
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software.  After this initial reading, and incubation period of 10 minutes is done, then the 
plate was read again using the Magellan software. 
Nitric Oxide Assay:  The initial step in the Nitric Oxide assay was to mix the necessary 
chemicals to make reagent 1 and 2.  Reagent 1 is made by weighing out 0.1 g of N-(1-
naphthyl) ethylenediamine dihydrochloride (NED) and dissolving in 100mL of distilled 
water.  Reagent 2 was made weighing out 1.0g of sulfaniladmide and dissolving in 
100mL of 5% phosphoric acid.  Aluminum foil was placed around the flask containing 
Reagent 1 and 2 and placed in the refrigerator.  The Standard solution is made by 
weighing out 0.069 g of sodium nitrite and dissolving in 500mL of distilled water.  Of 
this solution, 1mL is then placed in 9mL of distilled water.  Eight glass test tubes were 
used and 300µL of the standard solution were pipetted into tubes 1 and 2.  Of distilled 
water, 300µL were added into tubes 2-8.  A serial dilution was performed, starting with 
taking out 300µL from tube 2, and then stopping at tube 7.  Of the standards, 100µL were 
pipetted into the 96-well plate, and 100µL of the supernatants were also added into the 
96-well plate.  A working reagent was then prepared using reagents 1 and 2 by mixing 1 
part of Reagent 1 with one part of Reagent 2.  The total amount of working reagent was 
calculated, and then divided by 2 to determine the quantity of Reagent 1 and 2. Of the 
working reagent, 100µL were added into the 96-well plate.  The plate was incubated at 
room temperature for at least 5 minutes before analysis at 492nm and 540 nm.  Both 
parameters use the concentrations of 200, 100, 50, 25, 12.5, 6.25, 3.125, and 0 for the 
curve fit parameters. 
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Lactate Dehydrogenase (LDH) Assay:  The initial step in the LDH assay was to prepare 
the working reagent (mix 5 parts Buffer (R1) and 1 part Co-enzyme (R2). Of reagent, 
1.0mL is pipetted into the appropriate cuvette tubes and pre-wared in incubator (37˚C) for 
5 minutes.  The spectrophometer was calibrated using a blank tube with water only at 
340nm.  Supernatant samples (50µL) were added to the cuvettes containing the reagents, 
mixed, then were placed in incubator for 30 seconds.  The first absorbance (A1) was read 
and recording using the spectrophometer.  The samples are then placed back in the 
incubator for 30 minutes, and then A2 is read and recorded.  The change in absorbance 
((A2-A1)/30mins) multiplied by the factor 3376 yielded results in IU/L. 
Statistics and Graphing: Sigmaplot 12.0 software was used for the statistical analysis 
and one-way ANOVA data.  The preferred comparison option for one-way ANOVA was 
Dunnett’s and Tukey’s, however if this option was not available, Dunn’s method was 
used to compare the variables and evaluate significant differences, etc.  The SlideWrite 
software was use for the graph production.   Descriptive statistics was expressed as mean 
+/- standard error of the mean (SEM).  The data collected from the experiments was 
statistically analyzed using the SigmaSTAT software.  Group mean comparisons were 
determined using one-way analysis of variance (ANOVA) to determine if any difference 
differences existed among the groups. ANOVA used an F test to compare the mean of 
multiple groups initially to determine if differences exist. 
Multiple comparison testing was performed when significant differences were detected 
using ANOVA.  Several different types of multiple comparison procedures exist, 
including Dunnett, Dunn, and Tukey.  The Tukey posttest was used to determine which 
differences among the group means were statistically significant.  
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Protein Assay (Figures 3-5): 
The effects of Genistein (G), Thymoquinone (TQ), and 5-Fluorouracil (5-FU) on 
overall protein levels in FaDu cells were measured as a correlate to overall cell number 
and cell viability (Figures 3-5).  The IC50 doses (concentration found to inhibit cellular 
replication by 50%) determined at the 72-hour time point of G, TQ, and 5-FU were 25 
mM, 16 µM, and 16 µM respectively, informed by previous studies such as Williams et 
al 2015 and Lin et al 2001.  Cells treated with TQ displayed the greatest decrease in 
protein levels as compared to the untreated control group at all time points (24-72 hours).  
In particular, protein levels were significantly decreased by 68%, 76%, and 76% at 24, 
48, and 72 hours respectively as compared to untreated control.  5-FU significantly 
decreased protein levels, as compared to untreated control, at 48 and 72 hours by 51% 
and 96%, respectively.  In contrast, G did not significantly affect protein levels, as 
compared to the untreated control, at any time point.  As the concentrations of all drugs 
were chosen based on previously calculated IC50 values, the lack of G effect was 
surprising, but consistently noted.   
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Figure 3:  Average 24-hr cellular protein assay of FaDu cells treated with Genistein, 
Thymoquinone, and Fluorouracil.  Bar graph representing amount of cellular protein after 
treated with 25mM Genistein, 16µM TQ, and 16µM 5-FU and control that contained 
cells only.  Dunnett’s Method was used for multiple comparisons versus the control 
group.  Any significant differences (p<0.05) for Dunnett’s multiple comparison 
procedure of treatment group compared to the control are denoted with an asterisk (*).  
Normality Test (Shapiro-Wilk) Passed (P = 0.091) 
 
  
 *  
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Figure 4:  Average 48-hr cellular protein assay of FaDu cells treated with Genistein, 
Thymoquinone, and Fluorouracil.  Bar graph representing amount of cellular protein after 
treated with 25mM Genistein, 16µM TQ, and 16µM 5-FU and control that contained 
cells only.    Any significant differences (p<0.05) for Dunn’s multiple comparison 
procedure of treatment group compared to the control are denoted with an asterisk  
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
  
* 
* 
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Figure 5: Average 72-hr cellular protein assay of FaDu cells treated with Genistein, 
Thymoquinone, and Fluorouracil.  Bar graph representing amount of cellular protein after 
treated with 25mM Genistein, 16µM TQ, and 16µM 5-FU and control that contained 
cells only.    Any significant differences (p<0.05) for Dunn’s multiple comparison 
procedure of treatment group compared to the control are denoted with an asterisk (*).   
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
  
* 
* 
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Glut Assay (Figures 6-8): 
The effects of G, TQ, and 5-FU on overall glutathione (glut) levels in FaDu cells 
were measured as a correlate to overall cellular damage. Figures 6-8 display glutathione 
levels of cells when treated with previously determined IC50 doses of G, TQ, and 5-FU.  
G significantly decreased glutathione levels, as compared to the untreated control, at 24 
and 48 hours by 33% and 22%, respectively.  TQ significantly increased in glutathione 
levels at 48 hours by 200%, which was reversed to normal by 72 hours.  5-FU did not 
significantly affect glutathione levels, as compared to the untreated control, at any time 
point. 
** Although G displayed significant change in glutathione levels, G was removed as a 
treatment and replaced with EGCG (seen in the upcoming data) because EGCG was 
shown to have more overall significant effect.    
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Figure 6:  Average 24-hr intracellular glutathione assay of FaDu cells treated with 
Genistein, Thymoquinone, and Fluorouracil.  Bar graph representing oxidative 
damage/glut levels after treated with 25mM Genistein, 16µM TQ, and 16µM 5-FU and 
control that contained cells only.  Dunnett’s Method was used for multiple comparisons 
versus the control group.  Any significant differences (p<0.05) for Dunnett’s multiple 
comparison procedure of treatment group compared to the control are denoted with an 
asterisk (*).  
Normality Test (Shapiro-Wilk) Passed (P = 0.147) 
  
* 
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Figure 7:  Average 48-hr intracellular glutathione assay of FaDu cells treated with 
Genistein, Thymoquinone, and Fluorouracil.  Bar graph representing oxidative 
damage/glut levels after treated with 25mM Genistein, 16 µM TQ, and 16µM 5-FU and 
control that contained cells only. Any significant differences (p<0.05) for Dunn’s 
multiple comparison procedure of treatment group compared to the control are denoted 
with an asterisk (*).   
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
  
 
  
* 
* 
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Figure 8:  Average 72-hr intracellular glutathione assay of FaDu cells treated with 
Genistein, Thymoquinone, and Fluorouracil.  Bar graph representing oxidative 
damage/glut levels after treated with 25mM Genistein, 16 µM TQ, and 16µM 5-FU and 
control that contained cells only.    Any significant differences (p<0.05) multiple 
comparison procedure of treatment group compared to the control are denoted with an 
asterisk (*). 
The differences in the median values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference    (P = 0.289) 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
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Protein Assay Phase 1 (Figures 9-11; 12): 
The effects of TQ, EGCG, and 5-FU on overall protein levels in FaDu cells were 
measured again, as was 3 µM of EGCG, the IC50 dose as reported in Williams et al 2015 
(Figures 9-11).  TQ, EGCG, and 5-FU, as compared to the untreated control, did not 
significantly affect protein levels at any time point.  These results are not consistent with 
previous literature or with the results found in Figures 3-5, where TQ displayed 
significant decrease at all time points.   
The effects of each treatment in combination with laser on overall protein levels 
in FaDu cells were also measured (Figures 9-11).  The literature-based IC50 
concentrations for each treatment were used to treat the cells.  LLLT alone significantly 
increased protein levels, as compared to the untreated control, at 48 hours by 74%.  TQ + 
laser significantly increased protein levels, as compared to the untreated control, at 48 
hours by 20%, and significantly decreased protein levels, as compared to the untreated 
control at 48 hours by 68%.  TQ + laser also significantly decreased protein levels, as 
compared to LLLT, at 72 hours by 63%.  All other treatments did not significantly affect 
protein levels when compared to the untreated control or LLLT alone. 
An additional analysis evaluating the effects of 5-FU and 5-FU + laser on protein 
levels was performed to investigate what happens to protein levels at 96 hours (Figure 
12).  5-FU + laser significantly decreased protein levels, as compared to LLLT alone, at 
24 hours by 44%.  No other significant differences were observed.  The purpose of 
investigating just 5-FU at 96 hours is because we wanted to test the effects of this drug 
that is actually used in treating laryngeal and hypopharyngeal carcinomas and see the 
prolonged effects.  
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Figure 9: 24-hr Phase 1 cellular protein assay of FaDu cells treated with Thymoquinone, 
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.  
Bar graph representing amount of cellular protein after treated with 10 joules (1.05J/cm
2
) 
of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the 
treatments with laser, and control that contained cells only.   Any significant differences 
(p<0.05) for multiple comparison procedure of treatment group compared to the control 
are denoted with an asterisk (*).  
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 0.079). 
Normality Test (Shapiro-Wilk) Passed (P = 0.826) 
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Figure 10:  48-Hr Phase 1 cellular protein assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing amount of cellular protein after treated with 
10 joules (1.05J/cm
2
) of 830 nm laser 3µM EGCG, 16µM TQ, and16µM  5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*). 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
  
* 
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Figure 11:  72-Hr Phase 1 cellular protein assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing amount of cellular protein after treated with 
10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Any 
significant differences (p<0.05) for Dunn’s multiple comparison procedure of treatment 
group compared to the control are denoted with an asterisk (*).  Any significant 
differences (p<0.05) for Dunn’s multiple comparison procedure of treatment grouped 
compared to Control + Laser is denoted with a percent sign (%). 
Normality Test (Shapiro-Wilk) Passed (P = 0.522) 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
* % 
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Figure 12:  Average 24-72-96-hr cellular protein assay of FaDu cells treated with Laser, 
fluorouracil, and fluorouracil plus laser.  Bar graph representing amount of cellular 
protein after treated with 10 joules (1.05J/cm
2
) of 830 nm laser, 16µM 5-FU, a 
combination of these two treatments, and control that contained cells only.    Any 
significant differences (p<0.05) for Dunn’s multiple comparison procedure of treatment 
group compared to the control are denoted with an asterisk (*).   
72hrs/96hrs : The differences in the median values among the treatment groups are not 
great enough to exclude the possibility that the difference is due to random sampling 
variability; there is not a statistically significant difference    (P = 0.352), (P=.396) 
respectively 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
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Glut Assay (Figures 13-15; 16): 
The effects of TQ, EGCG, and 5-FU, at the same previously discussed 
concentrations, on overall glutathione levels in FaDu cells were measured as a correlate 
to overall cellular damage (Figures 13-15).  5-FU significantly increased glutathione 
levels, as compared to the untreated control, at 48 hours by 38%.  The other treatments 
did not significantly affect glutathione levels at any time point.   
The effects of each treatment in combination with laser on glutathione levels in 
FaDu cells were also measured (Figures 13-15).  The IC50 concentrations for each 
treatment were still used to treat cells.  LLLT alone significantly increased glutathione 
levels, as compared to the untreated control, at 48 hours by 20%.  TQ + laser significantly 
decreased glutathione levels, as compared to LLLT alone, at 24 hours by 27%.  5-FU + 
laser significantly increased glutathione levels, as compared to the untreated control, at 
48 hours by 41%.  The other treatments did not significantly affect glutathione levels at 
any time point.  
An additional analysis evaluating the effects of 5-FU and 5-FU + laser on 
glutathione levels was performed to investigate what happens to protein levels at 96 
hours in Figure 16. There are no significant differences in any time point.   
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Figure 13:  24-Hr Phase 1 intracellular glutathione assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing oxidative damage/glut levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunnett’s 
Method was used to for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple 
Comparison Procedure was done using a Tukey Test, and any significant differences 
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to 
Control + Laser is denoted with a percent sign (%). 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.229) 
Equal Variance Test: Passed (P = 0.910) 
 
% 
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Figure 14:  48-Hr Phase 1 intracellular glutathione assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing oxidative damage/glut levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*).  
Normality Test (Shapiro-Wilk) Passed (P = 0.543) 
 
* 
* 
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Figure 15:  72-Hr Phase 1 intracellular glutathione assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing oxidative damage/glut levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunn’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunn’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*).  
Normality Test (Shapiro-Wilk) Passed (P = 0.624) 
Equal Variance Test: Failed (P < 0.050) 
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Figure 16:  Average 24-72-96-hr intracellular glutathione assay of FaDu cells treated with 
treated with Laser, fluorouracil, and fluorouracil plus laser.  Bar graph representing 
oxidative damage/glut levels after treated with 10 joules (1.05J/cm
2
) of 830 nm laser, 
16µM 5-FU, a combination of these two treatments with laser, and control that contained 
cells only.    Any significant differences (p<0.05) for multiple comparison procedure of 
treatment group compared to the control are denoted with an asterisk (*).   
24 ,72hr,96 : The differences in the median values among the treatment groups are not 
great enough to exclude the possibility that the difference is due to random sampling 
variability; there is not a statistically significant difference   (P = 0.098), (P = 0.261), (P = 
0.136). 
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NO Assay Phase 1 (Figures 17-19): 
The effects of TQ, EGCG, and 5-FU on overall nitric oxide (NO) levels in FaDu 
cells were measured as a correlate to overall cellular stress (Figures 17-19).  EGCG 
displayed the greatest increase in NO levels, as compared to the untreated control, at all 
time points (24-72 hours).  In particular, NO levels were significantly increased by 180%, 
186%, and 556% at 24, 48, and 72 hours, respectively as compared to the untreated 
control. The other treatments did not show any significant differences at any time 
interval. 
The effects of each treatment in combination with laser on NO in FaDu cells were 
also measured (Figures 17-19).  EGCG + laser significantly increased NO levels, as 
compared to the untreated control, at 48 and 72 hours by 223% and 620%, respectively.  
EGCG + laser also significantly increased NO levels, as compared to LLLT alone, at 48 
and 72 hours by 600% and 603% respectively.  TQ + laser significantly increased nitric 
oxide levels, as compared to the untreated control and LLLT alone, at 72 hours by 441% 
and 407%, respectively.  The other treatments did not display any significant differences 
at any time intervals. 
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Figure 17:  24-Hr Phase 1 nitric oxide assay of FaDu cells treated with Thymoquinone, 
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.  
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm
2
) of 830 
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with 
laser, and control that contained cells only.  Dunn’s Method was used for multiple 
comparisons versus the control group.  Any significant differences (p<0.05) for Dunn’s 
multiple comparison procedure of treatment group compared to the control are denoted 
with an asterisk (*).    
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050)  
* 
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Figure 18:  48-Hr Phase 1 nitric oxide assay of FaDu cells treated with Thymoquinone, 
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.  
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm
2
) of 830 
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with 
laser, and control that contained cells only.  Dunnett’s Method was used for multiple 
comparisons versus the control group.  Any significant differences (p<0.05) for Dunnett’s 
multiple comparison procedure of treatment group compared to the control are denoted 
with an asterisk (*). An All Pairwise Multiple Comparison Procedure was done using a 
Tukey Test, and any significant differences (p<0.05) for Tukey multiple comparison 
procedure of treatment group compared to Control + Laser is denoted with a percent sign 
(%).   
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050)  
* 
* %  
# 
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Figure 19:  72-Hr Phase 1 nitric oxide assay of FaDu cells treated with Thymoquinone, 
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.  
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm
2
) of 830 
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with 
laser, and control that contained cells only.  Dunn’s Method was used for multiple 
comparisons versus the control group.  Any significant differences (p<0.05) for Dunn’s 
multiple comparison procedure of treatment group compared to the control are denoted 
with an asterisk (*).  Treatment groups compared to control + laser is denoted with a 
percent sign (%). 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
  
* 
* 
% 
* % 
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LDH Assay Phase 1 (Figures 20-22): 
The effects of TQ, EGCG, and 5-FU on overall lactate dehydrogenase (LDH) 
levels in FaDu cells were measured as a correlate to overall cellular damage and toxicity 
(Figures 20-22).  EGCG displayed the greatest increase in LDH levels, as compared to 
the untreated control, at all time points.  Specifically, LDH levels significantly increased 
by 600%, 900%, and 950% at 24, 48, and 72 hours, respectively.  5-FU significantly 
increased LDH levels, as compared to the untreated control, at 48 and 72 hours by 150% 
and 350%, respectively.   
The effects of each treatment in combination with laser on LDH levels in FaDu 
cells were also measured (Figures 20-22).  EGCG + laser significantly increased LDH 
levels, as compared to the untreated control, at 24, 48 and 72 hours by 725% and 650%, 
and 262%, respectively.  EGCG + Laser also significantly increased LDH levels, as 
compared to LLLT alone, at 24, 48 and 72 hours by 726% and 262%, and 775%, 
respectively.  5-FU + laser significantly increased LDH levels, as compared to the 
untreated control, at all time intervals.  Specifically, LDH levels significantly increased 
by 325%, 200%, and 500% at 24, 48, and 72 hours, respectively.  5-FU + laser also 
significantly increased LDH levels, as compared to LLLT alone, at all time intervals.  In 
particular, LDH levels significantly increased by 325%, 100%, and 500% at 24, 48, and 
72 hours, respectively.   
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Figure 20:  24-Hr Phase 1 lactate dehydrogenase assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing Lactate Dehydrogenase levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple 
Comparison Procedure was done using a Tukey Test, and any significant differences 
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to 
Control + Laser is denoted with a percent sign (%). 
Normality Test (Shapiro-Wilk) Passed (P = 0.993)  
* % 
* 
 %  
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Figure 21: 48-Hr Phase 1 lactate dehydrogenase assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing Lactate Dehydrogenase  levels after treated 
with  10 joules (1.05J/cm
2
) of 830 nm laser 3µM EGCG, 16µM TQ, and16µM  5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple 
Comparison Procedure was done using a Tukey Test, and any significant differences 
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to 
Control + Laser is denoted with a percent sign (%).    
Normality Test (Shapiro-Wilk) Passed (P = 0.051)  
* 
* 
* 
* % 
% 
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Figure 22:  24-Hr Phase 1 lactate dehydrogenase assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing lactate dehydrogenase levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple 
Comparison Procedure was done using a Tukey Test, and any significant differences 
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to 
Control + Laser is denoted with a percent sign (%).   
 
Normality Test (Shapiro-Wilk) Passed (P = 0.537) 
  
* 
* 
* 
* 
% 
% 
59 
 
Protein Assay Phase 2 (Figures 23-25): 
The effects of TQ, EGCG, and 5-FU on overall protein levels in FaDu cells were 
measured as a correlate to cell number and cell viability (Figures 23-25). Phase 2 differs 
from phase 1 because additional laser treatment was added each day rather than 
continuous laser treatment on day 0 for phase 1.  TQ, EGCG, and 5-FU did not display 
any significant difference at any time point.   
The effects of each treatment in combination with laser on protein levels in FaDu 
cells were also measured in Figures 23-25.  TQ + laser significantly decreased protein 
levels, compared to control and control + laser, at 72 hours by 60% and 66%, 
respectively.  5-FU + laser significantly decreased protein levels, as compared to control 
+ laser, at 72 hours by 49%.  The other treatments do not display any significant 
differences. 
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Figure 23:  24-hr Phase 2 cellular protein assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing amount of cellular protein after treated with 
10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Any 
significant differences (p<0.05) for multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*).  
The differences in the median values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference (P = 0.488) 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
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Figure 24:  48-hr Phase 2 cellular protein assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing amount of cellular protein after treated with 
10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Any 
significant differences (p<0.05) for multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*). 
The differences in the median values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.021) 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
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Figure 25:  72-Hr Phase 2 cellular protein assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing amount of cellular protein after treated with 
10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only. Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*). An All Pairwise Multiple 
Comparison Procedure was done using a Tukey Test, and any significant differences 
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to 
Control + Laser is denoted with a percent sign (%). 
Normality Test (Shapiro-Wilk) Passed (P = 0.131) 
  
* % 
% 
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Glut Assay Phase 2 (Figures 26-28): 
The effects of TQ, EGCG, and 5-FU on overall glutathione levels in FaDu cells 
were again measured as a correlate to overall cellular damage (Figures 26-28).  Phase 2 
consisted of laser treatment each day rather than continuous later treatment on day 0.  
EGCG significantly decreases glutathione levels at 48 hours by 36%.  The other 
treatments did not display any significant differences. 
The effects of each treatment in combination with laser on glutathione levels in 
FaDu cells were also measured in Figures 26-28.  The IC50 concentrations for each 
treatment were still used to treat cells.  There are no significant differences displayed at 
any time point. 
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Figure 26:  24-Hr Phase 2 intracellular glutathione assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing oxidative damage/glut levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only. Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*).   
 
Normality Test (Shapiro-Wilk) Passed (P = 0.229) 
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Figure 27:  48-Hr Phase 1 intracellular glutathione assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing oxidative damage/glut levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only. Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*).   
Normality Test (Shapiro-Wilk) Passed (P = 0.208) 
 
  
* 
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Figure 28:  72-Hr Phase 2 intracellular glutathione assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing oxidative damage/glut levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only. Dunn’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunn’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk  
 
Normality Test (Shapiro-Wilk) Passed (P = 0.088) 
  
67 
 
NO Assay Phase (Figures 29-31): 
The effects of TQ, EGCG, and 5-FU on overall NO levels in FaDu cells were 
measured as a correlate to overall cellular function (Figures 29-31). Phase 2 consisted of 
laser treatment each day rather than continuous later treatment on day 0. EGCG 
significantly increased NO levels, as compared to the untreated control, at 24, 48, and 72 
hours by 690%, 300%, and 3067%, respectively.  TQ significantly increased nitric oxide 
levels, as compared to the untreated control, at 48 hours by 125%.  The other treatments 
did not display any significant differences.  
The effects of each treatment in combination with laser on glutathione levels in 
FaDu cells were also measured in Figures 29-31.  EGCG + laser significantly increase 
nitric oxide levels, as compared to the untreated control, at 24, 48, and 72 hours by 733%, 
250%, and 2700%, respectively.  EGCG + laser also significantly increase nitric levels, 
as compared to laser alone, at 24, 48, and 72 hours by 734%, 192%, and 2233%, 
respectively.  The other treatments did not display any significant differences. 
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Figure 29:  24-Hr Phase 2 nitric oxide assay of FaDu cells treated with Thymoquinone, 
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.  
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm
2
) of 830 
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with 
laser, and control that contained cells only.  Dunnett’s Method was used for multiple 
comparisons versus the control group.  Any significant differences (p<0.05) for Dunnett’s 
multiple comparison procedure of treatment group compared to the control are denoted 
with an asterisk (*). An All Pairwise Multiple Comparison Procedure was done using a 
Tukey Test, and any significant differences (p<0.05) for Tukey multiple comparison 
procedure of treatment group compared to Control + Laser is denoted with a percent sign 
(%).    
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
* 
* 
%  
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Figure 30:  48-Hr Phase 2 nitric oxide assay of FaDu cells treated with Thymoquinone, 
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.  
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm
2
) of 830 
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with 
laser, and control that contained cells only.  Dunnett’s Method was used for multiple 
comparisons versus the control group.  Any significant differences (p<0.05) for Dunnett’s 
multiple comparison procedure of treatment group compared to the control are denoted 
with an asterisk (*). An All Pairwise Multiple Comparison Procedure was done using a 
Tukey Test, and any significant differences (p<0.05) for Tukey multiple comparison 
procedure of treatment group compared to Control + Laser is denoted with a percent sign 
(%).    
Normality Test (Shapiro-Wilk) Passed (P = 0.363)  
* 
* 
* % 
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Figure 31:  72-Hr Phase 2 nitric oxide assay of FaDu cells treated with Thymoquinone, 
Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and Fluorouracil + Laser.  
Bar graph representing Nitric oxide levels after treated with 10 joules (1.05J/cm
2
) of 830 
nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a combination of the treatments with 
laser, and control that contained cells only.  Dunn’s Method was used for multiple 
comparisons versus the control group.  Any significant differences (p<0.05) for Dunn’s 
multiple comparison procedure of treatment group compared to the control are denoted 
with an asterisk (*).   Treatment group compared to Control + laser denoted with a 
percent sign (%).  
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
  
* 
* %  
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LDH Assay Phase 2 (Figures 32-34): 
The effects of TQ, EGCG, and 5-FU on overall LDH levels in FaDu cells were 
measured as a correlate to overall cellular damage and toxicity (Figures 32-34). Phase 2 
consisted of laser treatment each day rather than continuous later treatment on day 0.  
EGCG significantly increase LDH levels, as compared to the untreated control, at 48 and 
72 hours by 320% and 483%, respectively. The other treatments did not display any 
significant differences. 
The effects of each treatment in combination with laser on LDH levels in FaDu 
cells were also measured (Figures 32-34).  EGCG + laser significantly increase LDH 
levels, as compared to untreated control, at 48 and 72 hours by 420% and 980%, 
respectively.  EGCG +laser also significantly LDH levels, as compared to LLLT alone, at 
48 and 72 hours by 150% and 210%, respectively.  5-FU + laser significantly increased 
LDH levels, as compared to untreated control, at 48 and 72 hours by 260% and 667%, 
respectively.  5-FU + laser also significantly increase LDH levels, as compared to LLLT 
alone, at 72 hours by 119%. The other treatments did not display any significant 
differences. 
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Figure 32:  24-Hr Phase 2 lactate dehydrogenase assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing lactate dehydrogenase levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunn’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunn’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*). 
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference (P = 0.655) 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.704).  
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Figure 33:  48-Hr Phase 2 lactate dehydrogenase assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing lactate dehydrogenase levels after treated 
with 10 joules (1.05J/cm
2
) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*).  An All Pairwise Multiple 
Comparison Procedure was done using a Tukey Test, and any significant differences 
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to 
control + laser is denoted with a percent sign (%).    
* 
* 
* 
% 
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Figure 34:  72-Hr Phase 2 lactate dehydrogenase assay of FaDu cells treated with 
Thymoquinone, Thymoquinone + Laser, EGCG, EGCG + Laser, Fluorouracil, and 
Fluorouracil + Laser.  Bar graph representing lactate dehydrogenase levels after treated 
with 10 joules (1.05J/cm2) of 830 nm laser, 3µM EGCG, 16µM TQ, and 16µM 5-FU, a 
combination of the treatments with laser, and control that contained cells only.  Dunnett’s 
Method was used for multiple comparisons versus the control group.  Any significant 
differences (p<0.05) for Dunnett’s multiple comparison procedure of treatment group 
compared to the control are denoted with an asterisk (*).  An All Pairwise Multiple 
Comparison Procedure was done using a Tukey Test, and any significant differences 
(p<0.05) for Tukey multiple comparison procedure of treatment group compared to 
control + laser is denoted with a percent sign (%).  
 Normality Test (Shapiro-Wilk) Passed (P = 0.994) 
 
  
* 
* 
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Discussion 
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Based on the findings of the current study, FaDu cells treated with 3 µM EGCG 
showed the greatest overall anti-cancer effect, in terms of promoting damage to FaDu 
cells, especially notable with increased changes in NO and LDH, compared to the 
untreated control.  In the first part of the experiment, TQ consistently showed a 
significant decrease in protein levels and glutathione levels; however, these effects were 
not consistent and are not displayed in the other protein analyses or any other analyses 
performed.  This drastic change in the results could be due to the possibility that the TQ 
stock used during the phase 1 and 2 experiments could have been too old, and was not as 
effective as when it was during the first set of experiments.  5-FU + laser displayed 
significant effects similar to EGCG when observing the LDH levels as compared to the 
untreated control; however, the results were not as consistent or effective as EGCG.  
Overall, the  laser seems to not have any significant effects by itself or when combined 
with the treatments. 
Many chemotherapeutic drugs stop cells in cycling through the cell cycle.  The 
cell cycle is divided into four parts:  G1, S, G2, and M. Cancer cells treated with the 
nucleoside analog chemotherapeutic agent, 5-FU, stops division of cells in the S phase of 
the cell cycle by being incorporated into RNA and DNA and halting translation, 
transcription, and replication, respectively (Wilkes et al 2008).  Limited and conflicting 
information exists regarding natural agents, genistein and TQ.  Both treatments have been 
shown to stop cells in the G0-G1 phase of the cell cycle and induce apoptosis possibly by 
increasing the ratio of Bax/Bcl-2 protein expression and decreasing Bcl-xL protein, 
which are type of anti- or pro-apoptotic regulatory proteins depending on the amount 
present in the cell (Gali-Muhtasib et al 2004; Shoieb et al 2003). Because G did not have 
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a significant effect on the cells, this treatment was later exchanged for EGCG, which was 
found in our lab to be effective against cancer cells, particularly hypopharyngeal 
carcinoma (Williams et al 2015). EGCG also arrests cells in the G0-G1 phase of the cell 
cycle by inhibiting the cyclin-dependent kinase complexes that are involved in cell cycle 
control in those phases (Gupta et al 2003; Liu et al 2015).  Most of these therapies and 
their effects on the cell cycle have been investigated with different types of cancer cells 
such as human esophageal/oral squamous cell carcinoma (Liu et al, 2015; Irimie et al, 
2015), human prostate carcinoma (Gupta et al,2003), and lung cancer cells (Flores-Perez 
et al, 2015).  Based on these previous studies, laryngeal and hypopharyngeal carcinomas 
seem like they would also be plausible cancer cell types that could be affected by the pro-
apoptotic effects of these therapies by cell cycle arrest. 
Throughout our study we noted that our findings were inconsistent, especially for 
TQ.  Our initial results show TQ to be effective at decreasing cell proliferation and 
inducing cell damage; but significant TQ effects were not noted throughout the entirety 
of the study.  Notably, the time when the first set of results was done several months 
earlier than the experiments including the laser was conducted. This could possibly hint 
at the idea that the stock of TQ used could have been old, and the effects were not 
presented accurately.  Many studies have displayed TQ as being an effective, putative 
treatment against different cancer cells.  For example, TQ induced p53- dependent 
apoptosis in human osteosarcoma cells (Roepke et al 2007), and increased apoptosis in 
ID8-NGL mouse ovarian cancer cells (Wilson et al 2015).  TQ was also found to 
significantly inhibit proliferation in human breast adenocarcinoma cells (Dehghani et al 
2015).  TQ’s pro-apoptotic effects, however, are not clearly and consistently seen in this 
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study. TQ likely becomes an inducer of glutathione as the cells are trying to recover and 
protect cells from the protein loss and damage due to treatment.  A change in glutathione 
levels is indicative of toxicological responses and oxidative stress, which can lead to 
apoptosis (Gokce et al 2016).  Due to these inconsistencies in our results, it would be 
plausible to re-evaluate the effects on TQ on FaDu cells.   
EGCG was a plausible treatment option for laryngeal or hypopharyngeal cancer in 
the present study.  Previous studies have shown that EGCG increases apoptosis and 
decreases cell proliferation in cancer cells such as lung cancer cells, human oral 
squamous cell carcinoma cells, and hypopharyngeal carcinoma cells (Flores-Perez et al 
2015; Lee et al 2015; Williams et al, 2015).   In the current study, EGCG was found to 
significantly affect nitric oxide and LDH levels, but not overall protein or glutathione 
levels. The increased nitric oxide levels due to EGCG are consistent with the study by 
Harpole et al (2015).    Nitric oxide has many versatile biological effects on the system, 
and increased nitric oxide levels could indicate either a positive or negative response on 
the system.  For example, increased nitric oxide levels could lead to oncogene expression, 
oxidative DNA damage, angiogenesis, and inhibition of DNA repair enzymes and/or 
dysregulation of apoptosis; however, nitric oxide can also generate apoptosis/death.    
This uncertainty of the meaning of the increased nitric oxide levels due to EGCG is 
clarified when evaluating the LDH levels. LDH is used to evaluate the presence of 
damage to, and toxicity of, cells.  The LDH levels were significantly increased by EGCG, 
indicating the FaDu cells were being damaged.  These results align with studies showing 
that EGCG displays pro-apoptotic effects on cancer cells (Lee et al, 2015; Liu et al, 
2015). 
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 Low level light therapy (LLLT) has been controversial in the literature in regards 
to treating different types of cancer.  LLLT induced cell death in a human colon 
carcinoma cell line (HCT 116) by increasing intracellular reactive oxygen species (ROS) 
concentrations, which were induced by mitochondrial damage (Saenko et al 2016).   The 
photons in LLLT absorb cytochrome-C oxidase, which is part of the mitochondrial chain.  
This reaction leads to increased electron transport, respiration, oxygen consumption, and 
ATP production (Tanupriya et al 2014).   Studies of LLLT by Kreisler et al (2002 and 
2003) showed enhanced cell proliferation, including on human laryngeal carcinoma in 
vitro, from 1.96-7.84 J/cm
2
 with LLLT of wavelength 809 nm. This is in contrast to some 
of the results of this study, where LLLT did not consistently show significant increase in 
overall protein levels, although in one set of cells from one duplicate experiment at 48 
hours, the protein assay did show a significant increase in protein levels, which aligned 
with the studies by Kreisler et al. Pinheiro et al (2002) reported that LLLT with 635 nm 
wavelength did not significantly stimulate laryngeal carcinoma cells, whereas, the LLLT 
with a wavelength of 670 nm wavelength significantly stimulated these cancer cells 
compared to the control, with every irradiation being 0.04-0.48J/cm
2
.  Other researchers, 
such as Werneck et al (2005) who used LLLT with wavelengths of 685 nm and 830 nm 
significantly increased the proliferation of laryngeal carcinoma cells.  Notably, the results 
of Renno et al (2007), reported an increase in normal osteoblast cells and reduction in 
osteosarcoma cells after treating with LLLT at 830 nm and a total energy impact of 10 
J/cm
2
. In our present study, we impacted a total energy of 10 J, which is equivalent to 
1.05 J/cm
2
 into each well using LLLT of 830 nm wavelength.  The conflicting results one 
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may observe in the literature, and between previous report and the present study, may be 
due to time of exposure, treatment and wavelength or parameters used.   
In the present study, we wanted to combine LLLT with the treatments, TQ, 
EGCG, and 5-FU, in order to possibly find a combination that would be most effective.  
Most combinations of the drug treatments with LLLT did not highlight a therapeutic 
benefit.  However, TQ + laser showed significant decrease in protein levels from one 
duplicate experiment at 48 and 72 hours, but these results may not be enough to make 
any conclusive analysis about TQ + laser.  Notably, 5-FU + laser significantly increased 
LDH levels, which is not seen in 5-FU alone, which could possibly mean that LLLT aids 
in cellular damage and toxicity.  LLLT combined with EGCG did show a significant 
difference showing similar results with the treatment of EGCG alone, but the 
combination did not prove to be more effective than the treatments alone.  In conclusion, 
our results consistently demonstrate reduction in hypopharyngeal tumor cells following 
treatment EGCG alone and when combined with laser therapy, but that there was no 
overall additive effect.  TQ and 5-FU results were inconsistent, and this study requires 
further investigation in order to clarify consistent findings and further treatments to test 
in-vivo. 
 Currently, researchers are trying to find out if certain drugs, vitamins, or other 
supplements can help prevent precancerous lesions from developing into laryngeal and 
hypopharyngeal carcinomas. Surgery techniques are also being refined in order to 
effectively take out laryngeal and hypopharyngeal tumors. More chemotherapeutic drugs 
are also being tested for these types of cancer (American Cancer Society, 2016). In this 
present study, there were many inconsistent findings that were contrary to previous 
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studies.  Although treatment with EGCG seems to be the most effective treatment 
compared to the others, there could be possible combinations of these drugs that could 
prove to be even more effective.  For future studies, it would be plausible to investigate 
the effects of EGCG in combination with 5-FU and TQ, and also with different 
wavelengths of LLLT other than 830 nm.  
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